olaparib,bevacizumab,rucaparib
roche,clovis,astrazeneca,merck
['solo1', 'paola1', 'olaparib', ' bev ', 'ariel4', 'ovarian']
#esmo2022 ovarian cancer and parp inhibitors. solo1 - 7 year update. better os but not statistically significant. 55 % pts needed further therapy. paola1- benift of bev over olaparib??
resistance to parp inhibitors . to find out early ? ?
ariel4 no os benifit. 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists